Krystal Biotech, Inc. (KRYS): Results of Operations and Financial Condition
Krystal Biotech, Inc. (KRYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q26-ex991xpressrelease.htm EX-99.1 Document Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results $119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launch
How this was made
The 30-second read
Why it matters
Traders can update models for near-term revenue durability (VYJUVEK), balance-sheet runway (cash and investments), and the probability-weighted timing of multiple upcoming clinical catalysts (notably IOLITE top-line in 4Q 2026).
Market read
The 8-K provides concrete commercial KPIs (revenue, gross margin, reimbursement approvals, prescriber base) and a dated catalyst schedule for 2H 2026 and 4Q 2026, which can drive repricing of biotech risk and timing.
What to watch
The filing emphasizes enrollment and expected timelines for multiple programs, but does not provide interim efficacy results for several registrational studies, leaving execution and regulatory risk as key uncertainties.
Background
This is an SEC Form 8-K (Item 2.02) with Krystal’s 2Q 2026 financial and operating results plus business updates across its VYJUVEK commercial franchise and pipeline programs.
Ticker impact
Krystal Biotech reported 2Q 2026 VYJUVEK revenue of $119.2M (+24% YoY), 95% gross margin, and $1.1B cash, plus 2H 2026 launch and readout plans.
Moderately positive bias for the stock as traders price in stronger commercial traction and clearer 2H 2026 catalysts.
The filing includes multiple specific, time-bound updates: revenue growth, reimbursement/prescriber expansion, expected international launches before year-end, and top-line readouts scheduled for 4Q 2026, all of which are actionable for biotech risk/reward positioning.
Market effects
Reinforces demand and reimbursement momentum for gene therapy in rare dermatology, potentially supporting sentiment toward similar commercial-stage rare-disease assets.
Highlights Europe pricing and reimbursement discussions (Germany, France, Italy, Spain) and UK pricing underway, which can influence regional rare-disease payer expectations.
International launch progress (Germany, France, Japan) and planned Spain/Italy launches before year-end can affect global rare-disease commercialization benchmarks.
Counterpoint
High gross margin and revenue growth may already be partially anticipated; the bigger swing factor is whether upcoming registrational readouts (4Q 2026) validate pipeline expansion beyond VYJUVEK.
Key entities
- issuerKrystal Biotech, Inc.
NASDAQ-listed company reporting 2Q 2026 results and providing pipeline and international launch updates.
- productVYJUVEK (beremagene geperpavec-svdt, B-VEC)
Commercial gene therapy for dystrophic epidermolysis bullosa; reported revenue growth, reimbursement approvals, and launch momentum.
- clinical_programIOLITE (KB803)
Registrational study fully enrolled in April, targeting a top-line data readout in 4Q 2026.
- clinical_programEMERALD-1 (KB801)
Registrational study continuing enrollment, targeting completion of ~60 patients before year-end.
